A carregar...
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma
The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...
Na minha lista:
| Publicado no: | Oncogene |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501768/ https://ncbi.nlm.nih.gov/pubmed/28263969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.526 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|